Tim Eisen
Overview
Explore the profile of Tim Eisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
5685
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oosterwijk-Wakka J, Houkes L, van der Zanden L, Kiemeney L, Junker K, Warren A, et al.
Neoplasia
. 2024 Dec;
60:101108.
PMID: 39724752
Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With...
2.
Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart G, et al.
Contemp Clin Trials Commun
. 2024 Nov;
42:101381.
PMID: 39555240
Clinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external factors can impact recruitment and reporting...
3.
Collinson F, Royle K, Swain J, Ralph C, Maraveyas A, Eisen T, et al.
Health Technol Assess
. 2024 Sep;
28(45):1-171.
PMID: 39250424
Background: There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial Design: A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment...
4.
Oza B, Eisen T, Stewart G, Bex A, Royston P, Meade A
J Clin Oncol
. 2022 Sep;
41(3):704-706.
PMID: 36166721
No abstract available.
5.
Diekstra M, Swen J, van der Zanden L, Vermeulen S, Boven E, Mathijssen R, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740506
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim...
6.
Stewart G, Welsh S, Ursprung S, Gallagher F, Jones J, Shields J, et al.
Br J Cancer
. 2022 Jun;
127(6):1051-1060.
PMID: 35739300
Background: Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the renal vein (RV) and/or inferior vena cava (IVC) has high peri-surgical morbidity/mortality. NAXIVA assessed the...
7.
Oza B, Eisen T, Frangou E, Stewart G, Bex A, Ritchie A, et al.
J Clin Oncol
. 2022 Feb;
40(16):1772-1782.
PMID: 35213214
Purpose: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation...
8.
Ursprung S, Woitek R, McLean M, Priest A, Crispin-Ortuzar M, Brodie C, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053497
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI...
9.
Ince W, Eisen T
Expert Opin Investig Drugs
. 2021 Dec;
30(12):1221-1229.
PMID: 34875200
Introduction: Pharmacological combinations using immune checkpoint inhibition (ICI), tyrosine kinase inhibition (TKIs), and mammalian target of rapamycin inhibitors (mTOR) have improved survival in metastatic clear cell renal cell cancer (mccRCC)....
10.
Field J, Vulkan D, Davies M, Baldwin D, Brain K, Devaraj A, et al.
Lancet Reg Health Eur
. 2021 Nov;
10:100179.
PMID: 34806061
Background: The NLST reported a significant 20% reduction in lung cancer mortality with three annual low-dose CT (LDCT) screens and the Dutch-Belgian NELSON trial indicates a similar reduction. We present...